Stephen Fink
Education
M.B.A., Columbia Business School; B.A., economics, Vassar College
Summary of Experience
Mr. Fink specializes in the application of economic analyses to complex business litigation matters. He has provided expert support in a broad range of cases, including antitrust matters, intellectual property (IP) cases, general business litigation, and regulatory proceedings. Mr. Fink has experience supporting experts across a variety of industries, including pharmaceuticals, high tech, agriculture, and media and entertainment. His case work has included antitrust claims against brand and generic drug manufacturers involving allegations of reverse-payment settlements, IP disputes involving biologic and biosimilar pharmaceutical manufacturers, and restraint of trade allegations involving exclusive licensing in the cosmetics industry. He has assisted attorneys, academic affiliates, and industry experts in all phases of complex litigation, including pretrial discovery, case strategy, expert reports, deposition support, and trial preparation.
-
Ten Years Post-Actavis: Lessons Learned and the Future of Reverse Payment Antitrust Cases
ABA Antitrust Committee, Oct. 24, 2023
2023 -
-
-
Reliable Analysis Is Key To Addressing Ascertainability
Law360, December 8, 2016
2016Cacciola S, Fink S
-
May 23, 2024
-
November 17, 2023
-
March 21, 2023
-
August 31, 2021
-
AG Feature Advancing Health Care Quality and Controlling Costs: A Q&A with Ashish Jha -
AG Feature Examining Trends in Drug Development: A Q&A with Michael Kinch -
Health Care Bulletin Meeting the Burden: The Predominance Requirement in Pharmaceutical Class Actions -
AG Feature What’s in the Record? Implications of the Asacol Case for Pharmaceutical Class Actions -
Health Care Bulletin The Myth of “Price Disconnects” in U.S. Pharma Markets
-
NewsAnalysis Group Experts Publish Article Examining Ascertainability in Class Certification